Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases

News

FacebookGoogleLinkedInTwitter

16 April, 2020   News

---
This article was originally published on April 2, 2020, by Financial Buzz on the digital media financialbuzz.com. The article has been replicated on Innoget's Innovation Blog by Innoget's Editorial Staff for information purposes.
---

– Preclinical data show unique platform addresses vascular leakage, which may support the health of patients during coronavirus infection

– Platform has been awarded grants from Canada and Europe for its development of therapeutics; additional grant submitted to the STTR program administered by the U.S. National Institutes of Health

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that its research partner Mannin Research Inc. (Mannin) is developing new therapeutics to treat a variety of vascular diseases, including the new coronavirus which originated in Wuhan, China, with a rapidly rising number of deaths and confirmed cases. Coronavirus has been declared a Global Health Emergency by the World Health Organization (WHO).

Mannin is developing a unique set of therapeutics that target a variety of vascular diseases. Its lead research platform targets the activation of the Angiopoietin-Tie2 signaling pathway. While Mannin is not generating a vaccine against infectious diseases, it is developing a new class of therapeutics that may increase the survival rate of patients by reducing endothelial dysfunction and severity of infectious and other diseases through enhancement of host-directed therapeutic response.

“We are working closely with our technology research partner Mannin to develop a potential adjunct treatment for various infectious diseases like the coronavirus. These types of outbreaks are not uncommon. H1N1, SARS, Ebola, pneumonia, influenza and others all can cause vascular leakage and respiratory distress in patients, which can be fatal in the most severe cases,” stated Q BioMed CEO Denis Corin.

Dr. George N. Nikopoulos, President and CEO of Mannin, “Mannin’s research team and collaborations in Canada, Germany, and the United States, are working to develop novel drugs to treat vascular leakage and endothelial dysfunction, which is common in severe cases of influenza, as well as in the current coronavirus outbreak. Seeing the potential to make positive impact upon patients’ lives, drives our team to strive further each day.”

In September 2019, the German state of Saxony awarded Mannin approximately a US $7.7 million grant to advance its novel therapeutics, including drugs and biologics that reduce endothelial dysfunction and loss of endothelial barrier integrity, which are central to the pathophysiology of viral and bacterial infections resulting in acute and severe lung injury. Recently, Mannin submitted a funding application to the Small Business Technology Transfer Grant administered by the U.S. National Institutes of Health to investigate specific applications of Mannin’s therapeutic platform.

About Q BioMed Inc.

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Please visit http://www.QBioMed.com and sign up for regular updates

About Mannin Research, Inc.

Mannin Research Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapeutics for vascular diseases using a novel mechanism of action. Mannin has a pipeline of novel therapeutics that can be developed from this research platform which would treat a spectrum of vascular diseases.

---
Keep up to date on Innoget's initiative to beat Covid-19 by following the dedicated channel where new innovation needs, novel technologies, news, and events are posted daily.

Other News

  • 21 April, 2022

Nomad Foods has partnered with the global innovation network Innoget to launch an open innovation portal to accelerate food tech collaborations. The portal will expedite solutions for some of the most pressing challenges facing the food industry, such as exploring new protein and packaging technologies, the Birds Eye parent said. It will be open to academics, subject experts, start-ups and SMEs that aim to develop new partnerships, beginnin...

Read more about this

Research and Development at PepsiCo changes the world, quite literally

  • 11 April, 2022

Shape the future at PepsiCo. Our scientists, technologists, and engineers are breaking new ground to make a positive impact on both consumers and our planet. R&D’s objective at PepsiCo is to shape the future by delivering a wide range of innovative foods and beverages—for brands like Frito-Lay, Gatorade, Pepsi-Cola, and Quaker —being one step ahead of consumer demand while raising the bar on sustainability. We proud...

Read more about this

  • 07 April, 2022

Luxembourg’s research federation has launched an open innovation platform to create more partnerships and accelerate the transfer of technological innovation. Announced by Research Luxembourg on 14 March, the platform hosts information on more than 80 technology offers and innovation needs ranging from healthtech to natural resource conservation and supply chain management. “We want to bring research and industry ...

Read more about this


Find More News